Vol 53 No 11

"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.

Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication

The trial will assess the effect of adding docetaxel to SOC hormone therapy plus apalutamide in mCSPC.

The phase 1 trial is assessing VIR-5500 as both a monotherapy and in combination with ARPIs in prostate cancer.

SBRT demonstrated favorable 4-year biochemical recurrence-free survival with a manageable safety profile.

"My pragmatic takeaway is that for patients who experience spasm or leak despite anticholinergics, this is a great thing to consider," says Mark D. Tyson II, MD, MPH.

The study is assessing the safety and tolerability of the CaverSTIM device for ED after surgical removal of the prostate.

Data showed that adding niraparib to AAP significantly improved radiographic progression-free survival in this patient population.

This announcement follows positive top-line data from a phase 1b/2a clinical trial of EG110A in patients with NDO following a spinal cord injury.

The addition of radiation after surgery improved clinical outcomes while not increasing severe late toxicity in this setting.

The review summarizes results from the OPTIMA II, ATLAS, and ENVISION trials.

The device features a 12 French working channel, the largest of any flexible single-use cystoscope.

Daniel Spratt, MD, presented data validating the PAM50 gene expression signature as the first predictive biomarker to guide hormone therapy in prostate cancer.

According to the authors, CAN-2409 may represent the first new treatment option for men with localized prostate cancer in over 2 decades.